See more : Yum China Holdings, Inc. (9987.HK) Income Statement Analysis – Financial Results
Complete financial analysis of ATI Inc. (ATI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ATI Inc., a leading company in the Manufacturing – Metal Fabrication industry within the Industrials sector.
- LIWANLI Innovation Co., Ltd. (3054.TW) Income Statement Analysis – Financial Results
- Favelle Favco Berhad (7229.KL) Income Statement Analysis – Financial Results
- HARSHIL AGROTECH LIMITED (HARSHILAGR.BO) Income Statement Analysis – Financial Results
- Webco Industries, Inc. (WEBC) Income Statement Analysis – Financial Results
- Ameresco, Inc. (AMRC) Income Statement Analysis – Financial Results
ATI Inc. (ATI)
About ATI Inc.
ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.17B | 3.84B | 2.80B | 2.98B | 4.12B | 4.05B | 3.53B | 3.13B | 3.72B | 4.22B | 4.04B | 5.03B | 5.18B | 4.05B | 3.05B | 5.31B | 5.45B | 4.94B | 3.54B | 2.73B | 1.94B | 1.91B | 2.13B | 2.46B | 2.30B | 3.92B | 3.75B | 3.82B |
Cost of Revenue | 3.37B | 3.12B | 2.47B | 2.69B | 3.48B | 3.42B | 3.08B | 2.97B | 3.63B | 3.84B | 3.79B | 4.34B | 4.37B | 3.56B | 2.65B | 4.16B | 4.00B | 3.74B | 2.89B | 2.49B | 1.87B | 1.74B | 1.86B | 2.00B | 1.78B | 2.95B | 2.83B | 2.90B |
Gross Profit | 802.60M | 714.20M | 333.20M | 292.80M | 637.80M | 630.30M | 449.00M | 162.50M | 85.70M | 378.60M | 252.60M | 693.20M | 813.20M | 490.30M | 408.40M | 1.15B | 1.45B | 1.20B | 650.20M | 244.90M | 63.80M | 163.30M | 265.70M | 461.90M | 513.50M | 973.20M | 916.30M | 913.90M |
Gross Profit Ratio | 19.23% | 18.62% | 11.90% | 9.82% | 15.47% | 15.58% | 12.74% | 5.18% | 2.30% | 8.96% | 6.25% | 13.78% | 15.69% | 12.11% | 13.37% | 21.69% | 26.58% | 24.21% | 18.37% | 8.96% | 3.29% | 8.56% | 12.49% | 18.77% | 22.36% | 24.81% | 24.47% | 23.95% |
Research & Development | 0.00 | 16.30M | 16.50M | 14.10M | 17.80M | 22.70M | 14.70M | 16.90M | 15.70M | 20.10M | 18.80M | 23.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 62.30M | 62.40M | 55.90M | 40.90M | 65.30M | 57.30M | 50.50M | 43.40M | 44.70M | 49.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 265.80M | 235.10M | 171.00M | 160.10M | 201.90M | 210.90M | 203.80M | 204.30M | 194.10M | 222.90M | 276.40M | 377.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 328.10M | 297.50M | 226.90M | 201.00M | 267.20M | 268.20M | 254.30M | 247.70M | 238.80M | 272.50M | 276.40M | 377.80M | 382.10M | 304.90M | 315.70M | 282.70M | 296.70M | 295.30M | 275.80M | 233.30M | 248.80M | 188.30M | 198.80M | 203.70M | 229.10M | 503.60M | 484.10M | 515.50M |
Other Expenses | 0.00 | -37.90M | 55.40M | -63.30M | -3.90M | -13.40M | 4.00M | 2.40M | 1.60M | 4.10M | 1.70M | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 328.10M | 297.50M | 226.90M | 201.00M | 267.20M | 268.20M | 254.30M | 247.70M | 238.80M | 272.50M | 276.40M | 377.80M | 382.10M | 304.90M | 315.70M | 282.70M | 296.70M | 295.30M | 275.80M | 233.30M | 248.80M | 188.30M | 198.80M | 203.70M | 324.40M | 503.60M | 484.10M | 515.50M |
Cost & Expenses | 3.71B | 3.42B | 2.69B | 2.89B | 3.75B | 3.68B | 3.33B | 3.22B | 3.87B | 4.12B | 4.07B | 4.72B | 4.75B | 3.86B | 2.96B | 4.44B | 4.30B | 4.04B | 3.17B | 2.72B | 2.12B | 1.93B | 2.06B | 2.20B | 2.11B | 3.45B | 3.31B | 3.42B |
Interest Income | 13.00M | 4.70M | 700.00K | 1.70M | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 105.80M | 87.40M | 96.90M | 94.40M | 99.00M | 101.00M | 133.80M | 124.00M | 110.20M | 108.70M | 65.20M | 71.60M | 92.30M | 62.70M | 19.30M | 3.50M | 4.80M | 0.00 | 350.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 146.10M | 152.70M | 153.70M | 151.30M | 160.60M | 166.40M | 170.80M | 180.30M | 189.90M | 176.80M | 189.90M | 194.00M | 174.40M | 141.50M | 132.60M | 118.80M | 102.90M | 84.20M | 77.30M | 76.10M | 74.60M | 90.00M | 98.60M | 99.70M | 95.30M | 109.00M | 98.50M | 105.30M |
EBITDA | 547.10M | 599.30M | 260.80M | -1.30B | 506.70M | 515.90M | 219.20M | -428.30M | -166.70M | 287.00M | 96.80M | 497.90M | 588.80M | 331.00M | 218.90M | 999.80M | 1.29B | 981.60M | 480.40M | 44.00M | -110.40M | 65.00M | 239.50M | 372.90M | 279.00M | 637.70M | 468.10M | 482.70M |
EBITDA Ratio | 13.11% | 13.60% | 10.92% | 5.76% | 12.56% | 12.48% | 10.20% | 2.79% | 1.03% | 6.80% | 4.15% | 10.13% | 11.68% | 8.08% | 7.38% | 18.71% | 22.91% | 19.87% | 13.57% | 1.61% | -2.21% | 5.74% | 11.25% | 15.16% | 12.15% | 16.25% | 12.50% | 12.65% |
Operating Income | 466.40M | 287.30M | 161.70M | 28.50M | 366.10M | 362.10M | 80.30M | -612.40M | -369.40M | 106.10M | -91.30M | 315.40M | 431.10M | 185.40M | 92.70M | 869.20M | 1.15B | 897.40M | 403.10M | -32.10M | -117.50M | 19.50M | 140.90M | 273.20M | 183.70M | 528.70M | 369.60M | 377.40M |
Operating Income Ratio | 11.17% | 7.49% | 5.78% | 0.96% | 8.88% | 8.95% | 2.28% | -19.54% | -9.93% | 2.51% | -2.26% | 6.27% | 8.32% | 4.58% | 3.03% | 16.37% | 21.03% | 18.17% | 11.39% | -1.17% | -6.06% | 1.02% | 6.62% | 11.10% | 8.00% | 13.48% | 9.87% | 9.89% |
Total Other Income/Expenses | -171.20M | 38.50M | -107.00M | -179.20M | -124.70M | -114.40M | -166.80M | -121.60M | -108.60M | -104.60M | -63.60M | -71.60M | -91.70M | -59.70M | -27.80M | -1.50M | -5.40M | -31.30M | -67.30M | 51.90M | -2.62B | -78.80M | -103.30M | -49.40M | -14.90M | -137.50M | 56.00M | 42.50M |
Income Before Tax | 295.20M | 162.00M | 10.60M | -1.48B | 241.60M | 247.70M | -86.50M | -734.00M | -478.00M | 1.50M | -154.80M | 244.00M | 339.40M | 125.70M | 64.90M | 860.10M | 1.15B | 869.20M | 307.10M | 19.80M | -2.80B | -103.80M | -36.40M | 208.80M | 174.20M | 391.20M | 475.20M | 384.70M |
Income Before Tax Ratio | 7.07% | 4.22% | 0.38% | -49.69% | 5.86% | 6.12% | -2.45% | -23.42% | -12.85% | 0.04% | -3.83% | 4.85% | 6.55% | 3.11% | 2.12% | 16.20% | 21.04% | 17.60% | 8.68% | 0.72% | -144.63% | -5.44% | -1.71% | 8.49% | 7.59% | 9.97% | 12.69% | 10.08% |
Income Tax Expense | -128.20M | 15.50M | 26.80M | 77.70M | -28.50M | 11.00M | -6.80M | -106.90M | -112.10M | -8.70M | -63.60M | 76.20M | 116.30M | 47.00M | 26.90M | 294.20M | 400.20M | 297.30M | -54.70M | -8.20M | 33.10M | -38.00M | -11.20M | 76.30M | 63.20M | 150.00M | 177.60M | 158.20M |
Net Income | 410.80M | 130.90M | -16.20M | -1.56B | 257.60M | 222.40M | -91.90M | -640.90M | -377.90M | -2.60M | 154.00M | 158.40M | 214.30M | 70.70M | 31.70M | 565.90M | 747.10M | 571.90M | 359.80M | 19.80M | -314.60M | -65.80M | -25.20M | 132.50M | 300.20M | 241.20M | 297.60M | 213.00M |
Net Income Ratio | 9.84% | 3.41% | -0.58% | -52.30% | 6.25% | 5.50% | -2.61% | -20.45% | -10.16% | -0.06% | 3.81% | 3.15% | 4.13% | 1.75% | 1.04% | 10.66% | 13.70% | 11.58% | 10.16% | 0.72% | -16.24% | -3.45% | -1.18% | 5.39% | 13.07% | 6.15% | 7.95% | 5.58% |
EPS | 3.29 | 1.03 | -0.13 | -12.33 | 2.05 | 1.52 | -0.83 | -5.97 | -3.52 | -0.02 | 1.44 | 1.49 | 2.09 | 0.73 | 0.33 | 5.71 | 7.35 | 5.76 | 3.77 | 0.23 | -3.89 | -0.82 | -0.31 | 1.60 | 3.15 | 4.90 | 3.73 | 2.65 |
EPS Diluted | 2.81 | 0.87 | -0.13 | -12.33 | 1.85 | 1.52 | -0.83 | -5.97 | -3.52 | -0.02 | 1.44 | 1.43 | 1.97 | 0.72 | 0.32 | 5.67 | 7.26 | 5.61 | 3.59 | 0.22 | -3.89 | -0.82 | -0.31 | 1.60 | 3.13 | 4.86 | 3.73 | 2.65 |
Weighted Avg Shares Out | 128.10M | 127.50M | 127.10M | 126.50M | 125.80M | 145.90M | 110.10M | 107.30M | 107.21M | 107.10M | 106.24M | 106.10M | 102.50M | 97.50M | 97.20M | 99.10M | 101.69M | 99.67M | 96.23M | 86.63M | 80.87M | 80.24M | 81.29M | 82.81M | 95.30M | 96.85M | 87.47M | 88.05M |
Weighted Avg Shares Out (Dil) | 150.00M | 151.20M | 127.10M | 126.50M | 146.50M | 145.90M | 110.10M | 107.30M | 107.30M | 107.10M | 106.80M | 116.60M | 113.90M | 98.70M | 98.10M | 99.80M | 102.96M | 102.34M | 100.84M | 90.49M | 80.87M | 80.24M | 81.29M | 82.81M | 95.91M | 96.85M | 87.47M | 88.05M |
Allegheny Technologies (ATI) Stock Sinks As Market Gains: Here's Why
ATI Announces Webcast for Third Quarter 2024 Results
Allegheny Technologies (ATI) Stock Dips While Market Gains: Key Facts
Allegheny Technologies (ATI) Declines More Than Market: Some Information for Investors
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Allegheny Technologies (ATI) Stock Falls Amid Market Uptick: What Investors Need to Know
Why Is Allegheny Technologies (ATI) Up 0.7% Since Last Earnings Report?
ATI CEO and CFO to speak at Morgan Stanley 12th Annual Laguna Conference
ATI's Board Authorizes $700 Million Share Buyback Program
ATI Announces Multi-Year $700 Million Share Repurchase Program, Upcoming Convertible Notes Redemption
Source: https://incomestatements.info
Category: Stock Reports